“I will never give up!”

Nobel laureate Robert Koch (1843 – 1910)
German physician and microbiologist,
discovered the Tuberculosis pathogen in 1882.

Who We Are

Austrianni GmbH is a pharmaceutical company with the mission to develop therapeutics for the prevention and treatment of tuberculosis.

ABOUT US

Technologies

Our technologies

We’ll do whatever it takes to generate new drugs for tuberculosis therapy. These drugs are either chemicals or biologicals, e.g., antibiotics or human antibodies. Traditionally, the discovery of either one of these medicines has required large teams, but recently, dedicated contract research organizations have taken over important parts of the processes. This allows us to concentrate on our core competencies that we have assembled in our company.

Small Molecules.

There are many enzymes that Mycobacterium tuberculosis cannot live without, and several antibiotics exploit this fact. Traditionally, antibiotics were found by testing large collections of microorganisms, or large collections of chemicals, for their ability to interfere with bacterial growth. Or chemical libraries were tested against an isolated target. In either case, only a tiny fraction of the vast chemical space of drug-like structures, estimated to consist of 63 ( 10⁶³ ) structures, can be covered.

MORE

Antibodies

Austrianni has unrestricted access to the powerful antibody discovery platform developed by the California company Trianni. This platform features the complete diversity of human antibody variable domains, which undergo natural V(D)J recombination and somatic hypermutation. Using this platform, Austrianni isolates fully human antibody therapeutics for the treatment of tuberculosis, with emphasis on multidrug resistant tuberculosis.

MORE

Antibodies

Austrianni has unrestricted access to the powerful antibody discovery platform developed by the California company Trianni. This platform features the complete diversity of human antibody variable domains, which undergo natural V(D)J recombination and somatic hypermutation. Using this platform, Austrianni isolates fully human antibody therapeutics for the treatment of tuberculosis, with emphasis on multidrug resistant tuberculosis.

MORE

Partners

News

Upcoming events

Members of the Austrianni team take part in conferences dedicated to the investigation of the host-pathogen relationship in TB, and in other conferences that deal with the biotech, pharma and healthcare business. In the following, some of these upcoming events are listed.

March 15 – 20, 2020

Ventura, CA, USA

GRC: Connecting B Cell Biology with Antibody Structure, Function and Applications

Antibodies are multi-faceted proteins that are capable of an array of important functions. They play a critical role in immune protection against invading pathogens and also play a role in a variety of clinically relevant inflammatory and autoimmune diseases.

May 18-19, 2020

Sydney, Australia

ICTMASE 2020: 14. International Conference on Therapeutic Monoclonal Antibodies and Side Effects

ICTMASE 2020: 14. International Conference on Therapeutic Monoclonal Antibodies and Side Effects aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Therapeutic Monoclonal Antibodies and Side Effects.

November 19-20, 2020

Singapore

ICTR 2020: 14. International Conference on Tuberculosis Research

ICTR 2020: 14. International Conference on Tuberculosis Research aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Tuberculosis Research.

January 16 – 20, 2020

Santa Fe, New Mexico, USA

Keystone Symposium: Tuberculosis: Immunity and Immune Evasion

Tuberculosis remains the most common fatal infectious disease worldwide due to the absence of a sufficiently effective vaccine. Two critical barriers to the development of an effective TB vaccine are the incomplete understanding of the mechanisms of protective immunity to TB, and of the mechanisms of immune evasion by M. tuberculosis.

IMPRINT

CONTACT

CAREER